Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BIO names exec VP-health

Executive Summary

Former FDA Deputy Commissioner for Policy Amit Sachdev joins the Biotechnology Industry Organization as executive VP for health April 18. Sachdev left FDA March 25. BIO is finalizing the details of a new top-level organizational structure, with an announcement expected the week of April 18. The association also has named former House Energy & Commerce Committee Majority Counsel Brent Delmonte as VP for legislative affairs and former HHS Chief of Staff Scott Whitaker as CEO Jim Greenwood's second-in-command (1"The Pink Sheet" April 11, 2005, In Brief)...

You may also be interested in...



BIO appoints second-in-command

Biotechnology Industry Organization is finalizing a title for former HHS Chief of Staff Scott Whitaker, who recently joined BIO as the number two executive under CEO James Greenwood (1"The Pink Sheet" Feb. 21, 2005, In Brief). Although BIO says Whitaker's official title has not yet been finalized, the group's website identifies Whitaker as the executive vice president. At a recent Center for Global Development meeting at Covington & Burling in Washington, D.C., Whitaker was introduced as BIO's exec VP and chief operating officer...

European SEAC Opinion Unchanged: Microplastics Must Be Out Of All Cosmetics Within Six Years

The final opinion of ECHA’s Socio-Economic Analysis Committee, published on 1 March, is largely unchanged from its July 2020 draft opinion with regard to microplastic in cosmetic products. That means industry may have to convince EU member state authorities that the restriction proposal has a serious proportionality problem.

QUOTED. 2 March 2021. Michael Coyle.

Representatives from cardiac monitoring device manufacturers and professional societies are working together to persuade Medicare carrier Novitas to reconsider its payment rates for extended cardiac monitoring. See what Michael Coyle, iRhythm’s CEO, said about it here.

Topics

UsernamePublicRestriction

Register

LL111799

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel